Stay up-to-date on the latest stock market upgrades and downgrades on Wall Street, including companies like Roku, Palo Alto ...

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

We recently made a list of Goldman Sachs’ Top Growth Investors: 34 Stocks With The Highest Investment For Growth. In this ...

A large majority of RRMS patients experienced no evidence of disease activity for up to six years on Tysabri, a real-world ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

"Samsung Biologics inks $668m manufacturing deal with European pharma " was originally created and published by ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

Happenings in Boston’s life sciences ecosystem this past week include the departure of a general partner from Apple Tree Partners for another firm, Kronos Bio seeks "strategic alternatives" and new ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 66%, bearish. Out ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are ...